Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,594,525 papers from all fields of science
Search
Sign In
Create Free Account
riociguat
Known as:
Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate
, Riociguatum
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Narrower (1)
Adempas
Guanylate Cyclase Stimulators [MoA]
riociguat 0.5 MG Oral Tablet
riociguat 1 MG Oral Tablet [Adempas]
riociguat 1.5 MG Oral Tablet [Adempas]
Expand
Broader (2)
Pyrazoles
Pyrimidines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Michael Gabrielly
,
D. Bourlier
,
+11 authors
X. Jaïs
Pulmonary hypertension
2018
Corpus ID: 81366636
There is no data on initial dual oral combination therapy in patients with inoperable CTEPH. The aim of our study was to evaluate…
Expand
Review
2018
Review
2018
What added value do these compounds bring ? New compounds for the treatment of pulmonary hypertension
R. Hullin
2018
Corpus ID: 56283032
Pulmonary hypertension (PH) was reported for the first time in 1891 when the autopsy of a patient with sudden death revealed…
Expand
2018
2018
Abstract 15095: Beneficial Effects of Riociguat on Hemodynamic Responses to Exercise in CTEPH Patients After Balloon Pulmonary Angioplasty
T. Aoki
,
K. Sugimura
,
+10 authors
H. Shimokawa
2018
Corpus ID: 216824986
Background: Balloon pulmonary angioplasty (BPA) improves resting hemodynamics in patients with chronic thromboembolic pulmonary…
Expand
2018
2018
New crystal form of riociguat, preparation method and use thereof
陈敏华
,
张炎锋
,
高慧
,
陈宇浩
,
张晓宇
2018
Corpus ID: 140521440
A crystal form CS4 and a crystal form CS9 of riociguat, and a preparation method and use thereof. The crystal form CS4 and the…
Expand
Review
2017
Review
2017
A Mixed Treatment Comparison Meta-Analysis of Pharmacotherapeutic Monotherapy and Placebo for Pulmonary Artery Hypertension
Matthew A. Silva
,
J. Donovan
,
+4 authors
Milka Njoroge
2017
Corpus ID: 79581804
Pulmonary artery hypertension (PAH) is rare, progressive, and difficult to treat. Earlier trials have found that active drug…
Expand
2016
2016
Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия
Array А. Шмальц
,
Array В. Горбачевский
2016
Corpus ID: 78591137
Last decades, several drugs for treatment of pulmonary hypertension have been implemented in clinical practice. Sildenafil…
Expand
2014
2014
Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension
G. Meyer
,
N. Galiè
,
+9 authors
H. Ghofrani
2014
Corpus ID: 71662698
Review
2013
Review
2013
Randomized clinical trials--removing obstacles.
Kyle L. Galbraith
New England Journal of Medicine
2013
Corpus ID: 54565355
n engl j med 369;23 nejm.org december 5, 2013 2268 The Authors Reply: Auger and Jamieson highlight the importance of pulmonary…
Expand
2013
2013
Hypertension: Riociguat therapy for pulmonary hypertension
Gregory B. Lim
Nature Reviews Cardiology
2013
Corpus ID: 19362355
Riociguat therapy for pulmonary hypertension Riociguat, a novel stimulator of soluble guanylate cyclase, improves walking…
Expand
2013
2013
Riociguat for pulmonary hypertension.
Post Mc
2013
Corpus ID: 68292699
To the Editor: With regard to the articles on the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase…
Expand